EP Patent

EP3307248A1 — Improved pharmaceutical formulation

Assigned to Nordic Group BV · Expires 2018-04-18 · 8y expired

What this patent protects

The present invention relates to a pharmaceutical formulations with reduced amount of lactose, for oral intake comprising 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2(3H)-one hydrochloride and up to 50% of anhydrous lactose, a process for the preparation of said formulation…

USPTO Abstract

The present invention relates to a pharmaceutical formulations with reduced amount of lactose, for oral intake comprising 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2(3H)-one hydrochloride and up to 50% of anhydrous lactose, a process for the preparation of said formulation and a method of treating chronic myeloproliferative disorder related symptoms by administering said formulation.

Drugs covered by this patent

Patent Metadata

Patent number
EP3307248A1
Jurisdiction
EP
Classification
—
Expires
2018-04-18
Drug substance claim
No
Drug product claim
No
Assignee
Nordic Group BV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.